Skip to main content
Midas Edge

Boundless Bio Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

BOLD$2.46+2.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Other Information

Item 5. Other Information.

Rule 10b5-1 Trading Arrangements

From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended June 30, 2024, our officers or directors adopted, modified, or terminated such trading arrangements as set forth below.

Action · Date · Trading Arrangement
Rule 10b5-1* · Non-Rule 10b5‑1** · Total Shares Subject to Plan · Expiration Date
Jami Rubin,Chief Financial OfficerAdoptMay 23, 2024X9,000April 29, 2025(1)
AdoptMay 24, 2024X32,537May 21, 2025(1)
Neil Abdollahian,Chief Business Officer
Jessica Oien,Chief Legal Officer and Corporate SecretaryAdoptMay 24, 2023X35,000May 23, 2025(1)
Klaus Wagner, M.D., Ph.D.,Chief Medical OfficerAdoptMay 24, 2024X68,000April 30, 2025(1)
Chris Hassig, Ph.D.,Chief Scientific OfficerAdoptMay 26, 2024X54,820September 30, 2025(1)
____________________* Intended to satisfy the affirmative defense of Rule 10b5-1(c)** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)(1)This trading plan may expire earlier if all transactions under the trading plan are completed before the scheduled expiration date.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.